Karyopharm Therapeutics (KPTI) Misses Q4 EPS by 571c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($5.71). Revenue for the quarter came in at $34.08 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Oppenheimer Starts Aktis Oncology (AKTS) at Outperform
• GSK raises $6.5B in multi-tranche bond offering via US markets
• Ormat Technologies (ORA) PT Raised to $145 at Oppenheimer